DNA syn­the­sis up­start rais­es $10M to scale op­er­a­tions

Ca­me­na Bio­science, a UK biotech, raised $10 mil­lion as it works on im­prov­ing the ac­cu­ra­cy of DNA syn­the­sis.

The Se­ries A, led by UK ven­ture cap­i­tal fund Mer­cia As­set Man­age­ment, will go to­ward con­tin­u­ing de­vel­op­ment of the biotech’s DNA syn­the­sis plat­form, and it will al­so be used to hire 10 more em­ploy­ees, the biotech an­nounced Mon­day. The com­pa­ny cur­rent­ly em­ploys 15 peo­ple.

Ca­me­na CEO and co-founder Steve Har­vey told End­points News that the com­pa­ny, which was found­ed in 2016, be­gan mak­ing rev­enue last year af­ter sign­ing com­mer­cial deals with “lead­ing con­sumers of syn­thet­ic genes,” ac­cord­ing to a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER